Zepbound works by activating both GIP and GLP-1 receptors through its active ingredient, tirzepatide. These hormone pathways can reduce appetite and calorie intake, increase feelings of fullness, affect glucose regulation, and slow gastric emptying, which can lead to weight loss when used with a reduced-calorie diet and physical activity.
What Is Zepbound?
Zepbound is a prescription injection containing tirzepatide. It is used with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction in eligible adults with obesity or adults with overweight plus at least one weight-related condition. It is also FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity.
The current FDA prescribing information identifies tirzepatide as a dual GIP and GLP-1 receptor agonist, not a GLP-1-only medication. DailyMed
Patients considering Zepbound can review the Zepbound weight-loss injection page for information about physician-guided use.
How Does Zepbound Work?
Zepbound contains tirzepatide, which activates two receptor pathways: GIP and GLP-1. Both pathways are involved in appetite regulation and metabolic signaling. The FDA label notes that GLP-1 helps regulate appetite and calorie intake, while GIP may add to the effect on food intake. DailyMed
The official Zepbound information from Eli Lilly also describes Zepbound as activating two hormone receptors, GIP and GLP-1, to reduce appetite and food intake. Zepbound
How GIP affects appetite and metabolism
GIP stands for glucose-dependent insulinotropic polypeptide. Tirzepatide activates GIP receptors, which are involved in metabolic and appetite-related signaling. GIP activity is one part of the reason tirzepatide differs from medications that activate only the GLP-1 receptor.
How GLP-1 affects hunger and fullness
GLP-1 is a hormone involved in appetite and calorie regulation. Tirzepatide activates GLP-1 receptors in areas involved in appetite control. This can reduce hunger and make it easier to feel satisfied after eating. DailyMed
How Zepbound affects food intake
The weight-loss effect is closely linked to appetite. The FDA label states that tirzepatide decreases calorie intake and that this effect is likely mediated by changes in appetite. In practical terms, a person may feel less hungry, become full with smaller portions, or have less interest in eating between meals. DailyMed
How Zepbound affects gastric emptying
Tirzepatide also delays gastric emptying, meaning food moves out of the stomach more slowly. This can contribute to fullness after eating. The effect on gastric emptying is strongest after the first dose and becomes less pronounced with continued use. DailyMed
Gastric emptying is only one part of the mechanism. Zepbound does not cause weight loss simply because food stays in the stomach longer. Its effects on appetite and calorie intake are central to the weight-loss process.
How Does Zepbound Cause Weight Loss?
The process can be understood as a chain:
GIP and GLP-1 receptor activation → appetite changes → greater fullness → lower food intake → lower calorie intake → reduction in body weight.
Tirzepatide also affects insulin and glucagon in a glucose-dependent manner and can improve insulin sensitivity. These metabolic effects are relevant to glucose regulation, but the weight-loss process is not simply a matter of “burning fat.” DailyMed
The FDA label reports that tirzepatide lowers body weight with greater fat-mass loss than lean-mass loss. The amount of weight a person loses can still differ based on dose, therapy duration, starting weight, health conditions, eating patterns, physical activity, and individual response. DailyMed
How Quickly Does Zepbound Start Working?
Zepbound begins acting in the body after an injection, but that does not mean a person will see major weight loss after the first dose.
Some people notice less hunger or earlier fullness during the first few weeks. Weight change can take longer to become visible. The starting dose is intentionally low, and the dose is increased gradually based on response and tolerability.
Current labeling states that Zepbound starts at 2.5 mg once weekly for four weeks. The 2.5 mg dose is for therapy initiation and is not a maintenance dose. After four weeks, the dose can increase in 2.5 mg steps when appropriate. DailyMed
Because tirzepatide reaches steady-state blood concentrations after about four weeks of once-weekly dosing, early results should not be judged from one injection or one week alone. DailyMed
Why Does the Zepbound Dose Increase Gradually?
The gradual dose schedule helps reduce gastrointestinal problems while the body adjusts to the medication.
The current prescribing information recommends 2.5 mg once weekly for the first four weeks, followed by 5 mg once weekly. Further increases can occur in 2.5 mg steps after at least four weeks on the current dose. Maintenance doses for weight reduction are 5 mg, 10 mg, or 15 mg once weekly, with 15 mg as the maximum recommended dose. DailyMed
Your prescriber decides the dose based on response and tolerability. A higher dose is not automatically better for each person.
How Much Weight Can You Lose With Zepbound?
Clinical trials show that weight loss can be substantial, but trial averages are not personal guarantees.
In the main 72-week weight-reduction study among adults with obesity or overweight without type 2 diabetes, average weight change was about:
| Zepbound dose | Average body-weight change at 72 weeks |
|---|---|
| 5 mg | −15.0% |
| 10 mg | −19.5% |
| 15 mg | −20.9% |
In the study of adults with overweight or obesity and type 2 diabetes, average weight change at 72 weeks was about 12.8% with 10 mg and 14.7% with 15 mg. DailyMed
The same FDA data show that results differ across individuals. In the study without type 2 diabetes, 85.1% of people receiving 5 mg, 88.9% receiving 10 mg, and 90.9% receiving 15 mg lost at least 5% of their starting body weight by week 72. DailyMed
These results came from clinical trials with diet and physical activity guidance, so they should not be interpreted as a guaranteed result for someone starting Zepbound.
What Does Research Show About Long-Term Zepbound Use?
The SURMOUNT trials provide important information about weight loss and continued use.
In SURMOUNT-1, adults with obesity or overweight without diabetes had greater weight reduction with tirzepatide than with placebo after 72 weeks. The study evaluated 5 mg, 10 mg, and 15 mg doses. New England Journal of Medicine
SURMOUNT-4 examined what happened when people who had already lost weight with tirzepatide continued the medication or switched to placebo. After the initial 36-week period, people who continued tirzepatide lost an additional 5.5% on average, while those switched to placebo regained 14% of their body weight during the following 52 weeks. JAMA Network
A 2026 analysis of SURMOUNT-4 also found that greater weight regain after tirzepatide withdrawal was linked with reversal of some earlier improvements in cardiometabolic measures. JAMA Network
A newer head-to-head study, SURMOUNT-5, compared tirzepatide with semaglutide in adults with obesity without type 2 diabetes. At 72 weeks, tirzepatide produced greater average reductions in body weight and waist circumference than semaglutide. New England Journal of Medicine
Who Can Take Zepbound?
The FDA approves Zepbound for adults with obesity or adults with overweight who have at least one weight-related medical condition, when used with a reduced-calorie diet and increased physical activity.
Zepbound is also approved for adults with obesity who have moderate to severe obstructive sleep apnea. DailyMed
Eligibility is not based on weight alone. A clinician should review medical history, current medications, health conditions, previous weight-management efforts, and possible contraindications before prescribing it.
Zepbound and Obstructive Sleep Apnea
Zepbound received FDA approval in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity. U.S. Food and Drug Administration
The same appetite and weight-loss mechanism contributes to this benefit. Lower calorie intake can lead to weight reduction, and weight reduction can improve factors that contribute to airway obstruction during sleep.
The FDA approval applies to a defined patient group, so a diagnosis of sleep apnea does not automatically mean Zepbound is appropriate.
Patients with sleep-related concerns can also review MMA’s sleep apnea information or discuss whether sleep apnea testing is appropriate.
Zepbound vs Ozempic vs Wegovy vs Mounjaro
These medications are often grouped together, but they are not the same drug.
| Medication | Active ingredient | Main receptor action | Main U.S. use |
|---|---|---|---|
| Zepbound | Tirzepatide | GIP + GLP-1 | Chronic weight management and OSA in eligible adults |
| Mounjaro | Tirzepatide | GIP + GLP-1 | Type 2 diabetes |
| Wegovy | Semaglutide | GLP-1 | Chronic weight management |
| Ozempic | Semaglutide | GLP-1 | Type 2 diabetes |
Zepbound and Mounjaro contain the same active ingredient, tirzepatide, while their FDA-approved uses differ. Ozempic and Wegovy both contain semaglutide, but they also have different approved uses. The current Mounjaro prescribing information identifies Mounjaro as a GIP and GLP-1 receptor agonist for type 2 diabetes. DailyMed
Patients comparing weight loss injections should look at the active ingredient, approved indication, health history, side-effect profile, dose schedule, and access rather than comparing brand names alone. MMA also provides information on Ozempic and Mounjaro.
Why Am I Not Losing Weight on Zepbound?
Not seeing a large change on the scale right away does not always mean the medication is not working.
Possible reasons include:
- You are still early in the dose-escalation period.
- You are using the starting dose.
- Your body is responding more slowly.
- Your calorie intake has not changed enough.
- Physical activity has remained low.
- Another medication or health condition affects weight.
- You have reached a temporary weight-loss plateau.
- Side effects are making it difficult to follow the prescribed plan.
Your clinician can review your progress, dose, side effects, eating pattern, activity, and health history before deciding whether a change is needed.
How Do You Know Zepbound Is Working?
Signs can include reduced hunger, feeling full sooner, smaller portions, fewer urges to eat between meals, and gradual changes in body weight or waist circumference.
A single weigh-in does not show the full response. Your clinician can track weight trends and other health measures across months.
What Should You Eat While Taking Zepbound?
Zepbound is used with a reduced-calorie diet and increased physical activity. Food choices should support adequate protein, fiber, fluids, vitamins, and minerals while fitting your medical needs.
Smaller meals may be easier to tolerate if nausea or fullness occurs. Large, heavy meals can worsen digestive symptoms for some people.
Your eating plan should also account for diabetes, kidney disease, digestive conditions, medications, and other health factors when present.
Zepbound Side Effects and Safety
The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, belching, hair loss, and gastroesophageal reflux disease. The current FDA label also lists serious risks that require medical attention. DailyMed
Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in people with a serious hypersensitivity reaction to tirzepatide or its ingredients. DailyMed
The label also warns about severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease, pancreatitis, hypersensitivity, hypoglycemia when used with certain diabetes medicines, diabetic retinopathy complications, and pulmonary aspiration during general anesthesia or deep sedation. DailyMed
Zepbound can delay gastric emptying and may affect the absorption of some oral medicines. People using oral hormonal contraceptives have specific guidance after starting Zepbound and after dose increases. Pregnancy also requires prompt discussion with the prescribing clinician because weight loss during pregnancy is not recommended. DailyMed
Anyone taking Zepbound should tell their healthcare team about other medications and any planned procedure requiring anesthesia or deep sedation.
What Happens When You Stop Zepbound?
Weight regain can occur after Zepbound is stopped.
In SURMOUNT-4, participants who had received tirzepatide for 36 weeks and then switched to placebo regained an average of 14% of their body weight during the following 52 weeks, while those who continued tirzepatide lost an additional 5.5% during that period. JAMA Network
This does not mean each person will regain the same amount. It shows why long-term weight management may require an ongoing plan rather than stopping medication as soon as the scale changes.
How Manhattan Medical Arts Can Help With Zepbound
Zepbound is not the right medication for each person who wants to lose weight. A medical evaluation can help determine whether tirzepatide fits your health history, current medications, weight-related conditions, and goals.
Dr. Syra Hanif, M.D. can review your medical history and discuss prescription weight-management options, expected monitoring, side effects, nutrition, activity, and long-term planning. Manhattan Medical Arts also provides weight management counseling for patients who need ongoing support.
Frequently Asked Questions
Is Zepbound a GLP-1 medication?
Zepbound is a dual GIP and GLP-1 receptor agonist. It contains tirzepatide, which activates both receptors rather than acting on the GLP-1 receptor alone.
Does Zepbound work after the first injection?
Zepbound begins acting after injection, but noticeable appetite or weight changes can take time. The starting dose is low and increases gradually based on response and tolerability.
How long does Zepbound take to cause weight loss?
Some people notice appetite changes within the first few weeks. Measurable weight loss develops across months, with larger changes seen with continued use.
Why does Zepbound reduce appetite?
Tirzepatide activates GIP and GLP-1 receptors involved in appetite regulation. These effects can reduce hunger and calorie intake, helping support weight loss.
Is Zepbound the same as Mounjaro?
Both contain tirzepatide and activate GIP and GLP-1 receptors. Their FDA-approved uses differ: Zepbound is approved for chronic weight management and certain adults with obesity-related OSA, while Mounjaro is used for type 2 diabetes.
Why am I not losing weight on Zepbound?
Early therapy, dose escalation, individual response, diet, activity, medications, and health conditions can affect results. A clinician can review your progress before changing the plan.
Can you regain weight after stopping Zepbound?
Yes. Clinical research shows that weight regain can occur after tirzepatide is withdrawn. The amount varies, and long-term weight management may require continued medical follow-up.
Does Zepbound work without diet and exercise?
Zepbound is FDA-approved for use with a reduced-calorie diet and increased physical activity. Medication should be part of a broader weight-management plan when prescribed.
Can Zepbound help with sleep apnea?
Yes. Zepbound is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity. A clinician should determine whether this indication applies to you.
Is Zepbound safe for everyone?
No. Zepbound has contraindications and warnings, including a contraindication for personal or family history of MTC or MEN 2. Your medical history and current medicines should be reviewed before use.
Disclaimer
This blog is for informational & educational purposes only and does not intend to substitute any professional medical advice or consultation. For any health-related concerns, please consult with your physician, or call 911.
-
About The Author
Dr. Syra Hanif M.D.Board Certified Primary Care Physician
Dr. Syra Hanif is a board-certified Primary Care Physician (PCP) dedicated to providing compassionate, patient-centered healthcare.
Read More

